Drugs / STP705
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05422378 | Aug 2022 → Feb 2023 | abdominal obesity-metabolic syndrome | Sirnaomics | Completed | No outcome recorded |
| Phase 1 | NCT04676633 | Mar 2021 → Jan 2023 | cholangiocarcinoma, hepatocellular carcinoma | Sirnaomics | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05196373 | Jun 2023 → Dec 2024 | reactive cutaneous fibrous lesion | Sirnaomics | Unknown | No outcome recorded |
| Phase 1/2 | NCT05421013 | Aug 2022 → Mar 2023 | skin squamous cell carcinoma in situ | Sirnaomics | Completed | No outcome recorded |
| Phase 1/2 | NCT04293679 | Mar 2019 → Oct 2020 | Bowen disease of the skin | Sirnaomics | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04844983 | May 2021 → Aug 2022 | skin squamous cell carcinoma in situ | Sirnaomics | Completed | No outcome recorded |
| Phase 2 | NCT04844840 | Apr 2021 → May 2023 | keloid | Sirnaomics | Completed | No outcome recorded |
| Phase 2 | NCT04669808 | Dec 2020 → Feb 2023 | basal cell carcinoma | Sirnaomics | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT02956317 Comparator | Jan 2017 → Jan 2018 | reactive cutaneous fibrous lesion | Sirnaomics | Completed | No outcome recorded |
| Phase 2 | NCT07677683 Comparator | Jul 2026 → Jul 2027 expected | — | Sirnaomics | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STP705 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05421013 ↗ |
| Action | Inhibit | “downregulate TGF-β1 and COX-2 expression” NCT04669808 ↗ |
| Modality | Small interfering RNA (siRNA) | “composed of two siRNA oligonucleotides” NCT04669808 ↗ |
| Route | Other | “The administration route would be intra-dermal injection.” NCT02956317 ↗ |